Sporadic Myotonic Dystrophy Type 2 in a Japanese Patient

  • Miyashita Koichi
    Department of Neurology, Mie University Graduate School of Medicine, Japan
  • Ii Yuichiro
    Department of Neurology, Mie University Graduate School of Medicine, Japan
  • Matsuyama Hirofumi
    Department of Neurology, Mie University Graduate School of Medicine, Japan
  • Niwa Atsushi
    Department of Neurology, National Mie Hospital, Japan
  • Kawana Yosuke
    Department of Neurology, Saiseikai Matsusaka General Hospital, Japan
  • Shibata Soshi
    Department of Neurology, Suzuka Chuo General Hospital, Japan
  • Minami Narihiro
    Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, Japan Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan
  • Nishino Ichizo
    Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, Japan Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan
  • Tomimoto Hidekazu
    Department of Neurology, Mie University Graduate School of Medicine, Japan

この論文をさがす

説明

<p>We herein report a Japanese patient with myotonic dystrophy type 2 (DM2), which is rare in Japan. A 64-year-oldman had proximal muscle weakness and grip myotonia. Electromyography showed myotonic discharges, but dystrophia-myotonica protein kinase (DMPK) was negative for CTG repeats. A muscle biopsy revealed increased central nuclei, pyknotic nuclear clumps and muscle fiber atrophy, mainly in type 2 fibers, raising the possibility of DM2. The diagnosis was genetically confirmed by the abnormal CCTG repeat size in cellular nucleic acid-binding protein (CNBP) on repeat-primed polymerase chain reaction, which was estimated to be around 4,500 repeats by Southern blotting. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 62 (20), 3027-3031, 2023-10-15

    一般社団法人 日本内科学会

参考文献 (17)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ